News

Revolutions Medical has initiated the mass manufacturing process for the FDA approved RevVac, an easy to use, single-handed vacuum safety syringe. By hitting its primary milestone, RevMed satisfies

Alexza Pharmaceuticals (Alexza) has submitted its New Drug Application (NDA) for Staccato loxapine (AZ-004) to the FDA. AZ-004 is an inhalation product candidate being developed for the rapid

Manchester Pharmaceuticals has reported the availability of Chenodal 250mg(chenodiol tablets). The FDA has approved Chenodal for patients suffering from gallstones, in whom, surgery poses an unacceptable health risk

Arid Pharmaceuticals has presented updated clinical data from its Phase 2 study evaluating oral Ridaforolimus in combination with Trastuzumab (Herceptin) in patients with resistant, metastatic breast cancer. As

Celldex Therapeutics (Celldex) has reported positive results from a Phase 2 study of CDX-011 (formerly CR011-vcMMAE), in patients with heavily pre-treated, locally advanced or metastatic breast cancers. Reportedly,

ProImmune has launched CFSE T cell proliferation assays for immunogenicity risk assessment. The new assays form part of ProImmune’s Reveal Immunogenicity system, a suite of tools used in

Celsion has completed the enrollment and treatment of the first patient in China, as part of Phase III ThermoDox Heat trial for the treatment of hepatocellular carcinoma (HCC).

ChemGenex Pharmaceuticals (ChemGenex) and Hospira have entered into an exclusive agreement to license, develop and commercialise the former’s omacetaxine mepesuccinate, a targeted cytotoxic pharmaceutical product, in Europe, the

PharmaVigilant has introduced I-Builder 2.0, a study-building solution that is expected to ease the study build process and technology transfer for sponsors. I-Builder can support multiple users for